Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.54 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 5/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6960733 | 0.85 | SCN10A (0.53) | SCN10AKDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL5956595 | 0.84 | ACACA (0.43) | SCN10AABL1ADORA3BCRMAPT | |
| SCHEMBL6231313 | 0.83 | RAB9A (0.46) | KDM5AKDM4CKDM5BKDM4EMAPT | |
| SCHEMBL5907457 | 0.81 | KDM1A (0.38) | KDM5AKDM2BKDM4CKDM5BABL1 | |
| SCHEMBL5956384 | 0.80 | SCN10A (0.47) | SCN10AKDM5AKDM2BKDM4CKDM5B | |
| SCHEMBL5956396 | 0.79 | CYP1A2 (0.39) | KDM5BABL1BCR | |
| SCHEMBL5956698 | 0.79 | EGFR (0.40) | ABL1BCR | |
| SCHEMBL5907479 | 0.79 | PRKAB2 (0.47) | — | |
| SCHEMBL5907494 | 0.77 | FKBP1A (0.52) | KDM4EMAPT | |
| SCHEMBL5956373 | 0.76 | WNK1 (0.45) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | SCN10A 3494/4885KDM5A 353/4885KDM2B 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.